228 related articles for article (PubMed ID: 38389092)
1. [
Rosar F; Burgard C; Larsen E; Khreish F; Marlowe RJ; Schaefer-Schuler A; Maus S; Petto S; Bartholomä M; Ezziddin S
Cancer Imaging; 2024 Feb; 24(1):27. PubMed ID: 38389092
[TBL] [Abstract][Full Text] [Related]
2. Detection efficacy of [
Rosar F; Khreish F; Marlowe RJ; Schaefer-Schuler A; Burgard C; Maus S; Petto S; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2899-2909. PubMed ID: 37148297
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. [
Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
[TBL] [Abstract][Full Text] [Related]
5. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
6. An
Dietlein F; Kobe C; Vázquez SM; Fischer T; Endepols H; Hohberg M; Reifegerst M; Neumaier B; Schomäcker K; Drzezga AE; Dietlein M
J Nucl Med; 2022 Apr; 63(4):573-583. PubMed ID: 34326129
[TBL] [Abstract][Full Text] [Related]
7. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
8. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
[TBL] [Abstract][Full Text] [Related]
9. 89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CT.
Rosar F; Bartholomä M; Maus S; Privé BM; Khreish F; Franssen GM; Derks YHW; Nagarajah J; Ezziddin S
Clin Nucl Med; 2022 May; 47(5):435-436. PubMed ID: 35234197
[TBL] [Abstract][Full Text] [Related]
10. Total-body PET/CT with half-dose [
Liu Y; Li L; Qin Y; Chen Z; Zhao H; Wang X; Chen R
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):581-589. PubMed ID: 37819451
[TBL] [Abstract][Full Text] [Related]
11.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
12. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
[TBL] [Abstract][Full Text] [Related]
13.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
14. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging
Chen MY; Franklin A; Yaxley J; Gianduzzo T; McBean R; Wong D; Tatkovic A; McEwan L; Walters J; Kua B
BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330
[TBL] [Abstract][Full Text] [Related]
15. Head-to-head comparison of [
Wang G; Hong H; Zang J; Liu Q; Jiang Y; Fan X; Zhu Z; Zhu L; Kung HF
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1052-1062. PubMed ID: 34557930
[TBL] [Abstract][Full Text] [Related]
16.
Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
[TBL] [Abstract][Full Text] [Related]
17. Impact of uptake time on image quality of [
van der Sar ECA; Viol SLM; Braat AJAT; van Rooij R; Lam MGEH; de Jong HWAM; de Keizer B
Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract][Full Text] [Related]
19. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
